血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎患者的临床效果

目的探讨血必净注射液联合人免疫球蛋白治疗重症病毒性肺炎患者的临床效果。方法选取2018年10月至2020年1月沈阳市第五人民医院收治的113例重症病毒性肺炎患者作为研究对象,将所有患者按照入院序号,单号入观察组,双号入对照组。对照组患者进行纠正电解质紊乱、呼吸辅助治疗等常规治疗基础上给予人免疫球蛋白静脉注射,观察组在对照组基础上采用血必净注射液治疗。比较两组炎症介质、免疫功能指标、不适症状消失时间。结果两组患者治疗前白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)比较,差异无统计学意义(P>0.05);治疗后,两组IL-6、hs-CRP、TNF-α降低,且观察组低于对照组,差异有统计学意义(P<0.05)。两组患者治疗前免疫球蛋白G(IgG)、免疫球蛋白M(IgM)比较,差异无统计学意义(P>0.05);治疗后,两组IgG、IgM升高,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组患者发热消失时间、气喘消失时间、咳嗽消失时间、乏力缓解时间、病毒核酸转阴时间短于对照组,差异有统计学意义(P<0.05)。结论对重症病毒性肺炎患者使用人免疫球蛋白与血必净进行联合治疗,能调节免疫功能,减轻炎症反应,快速缓解不适症状,疗效确切。

Clinical Effect of Xubijing Injection Combined with Human Immunoglobulin in the Treatment of Patients with Severe Viral Pneumonia

Objective To explore the clinical effect of Xubijing Injection combined with human immunoglobulin in the treatment of patients with severe viral pneumonia. Methods A total of 113 patients with severe viral pneumonia admitted to Shenyang Fifth People’s Hospital from October 2018 to January 2020 were selected as the research objects, and were divided into an observation group(odd number) and a control group(even number) according to the order of admission. Patients in the control group were given intravenous injection of human immunoglobulin on the basis of conventional treatments such as correction of electrolyte disturbances and respiratory adjuvant therapy. The observation group was treated with Xuebijing Injection plus intravenous injection of human immunoglobulin on the basis of conventional treatments such as correction of electrolyte disturbances and respiratory adjuvant therapy. Inflammatory mediators, immune function indicators, discomfort symptoms disappear time in the 2 groups were compared. Results Before treatment, there was no significant difference in interleukin-6(IL-6), high-sensitivity C-reactive protein(hs-CRP), and tumor necrosis factor-α(TNF-α) between the 2 groups of patients(P>0.05);after treatment, the levels of IL-6, hs-CRP, and TNF-α decreased in the 2 groups, and the observation group was lower than the control group, the difference was statistically significant(P<0.05). There was no significant difference in immunoglobulin G(IgG) and immunoglobulin M(IgM) between the 2 groups before treatment(P>0.05);after treatment, the IgG and IgM in the 2 groups increased, and the observation group was higher in the control group, the difference was statistically significant(P<0.05). The comparison of immunoglobulin G(IgG) and immunoglobulin M(IgM) between the 2 groups of patients before treatment was not statistically significant(P>0.05);the time of fever disappearance, asthma disappearance time, cough disappearance time, fatigue relief time, and viral nucleic acid turning negative time in the observation group were shorter than those in the control group, and the difference was statistically significant(P<0.05). Conclusion Human immunoglobulin combined with Xuebijing Injection for patients with severe viral pneumonia can regulate the immune function, reduce the inflammatory response, and quickly relieve the uncomfortable symptoms, with definite curative effects.